Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 10 clinical trials
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

This is a Phase Ib/IIb, randomized, two-cohort, open-label, multicenter study of intravesical N-803 plus BCG versus BCG alone, in BCG nave patients with high-grade NMIBC.

  • 95 views
  • 19 Mar, 2021
  • 24 locations
Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer

) undergoing treatment with Intravesical BCG. BCG is a weakened form of the bacterium Mycobacterium bovis that does not cause disease. It is used in a solution to stimulate the immune system in the treatment

  • 0 views
  • 18 Feb, 2021
  • 1 location
ADAPT-BLADDER: Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder

examining intravesical BCG in combination with novel immunotherapy agents (durvalumab), novel immunotherapy in combination with radiation (durvalumab + EBRT), or retreatment with intravesical BCG. In

intravesical bcg
bladder carcinoma
durvalumab
carcinoma
transurethral resection of bladder tumor
  • 47 views
  • 25 Jan, 2021
  • 11 locations
Intravesical Gemcitabine and Docetaxel for BCG na ve Non-muscle Invasive Bladder Cancer

, randomized phase 3 trial comparing the experimental combination therapy and standard of care intravesical BCG therapy.

intravesical bcg
invasive bladder cancer
bcg vaccine
docetaxel
carcinoma
  • 0 views
  • 25 Jan, 2021
  • 1 location
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

This is a Phase II/III, open-label, single-arm, multicenter study of intravesical BCG plus N-803 in patients with BCG unresponsive high grade non-muscle invasive bladder cancer (NMIBC). All

intravesical bcg
invasive bladder cancer
carcinoma
cancer
transitional cell carcinoma
  • 290 views
  • 19 Mar, 2021
  • 36 locations
Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer

The purpose of this study is to test the safety of avelumab and Bacille Calmette-Guerin (BCG) and see what effects (good and bad) that this combination treatment has on subjects with recurrent bladder cancer.

avelumab
invasive bladder cancer
bladder cancer
bladder tumor
cancer
  • 8 views
  • 24 Jan, 2021
  • 1 location
Immunological Response of Bladder Cancer Patients Under BCG

Bladder cancer (BC) is one of the most common cancers worldwide and the most successful example of vaccine in cancer treatment, representing an efficient model for studying the importance of systemic and local immune mechanisms. Despite being the standard of treatment for the last 40 years, the exact mode of …

  • 0 views
  • 08 May, 2021
  • 1 location
Surveillance of High-grade Non-muscle Invasive Bladder Tumours Using the Xpert Bladder Cancer Monitor

The study aims to evaluate the potential clinical impact of a highly sensitive urinary marker, the Xpert Bladder Cancer Monitor, regarding possible reduction in number of flexible cystoscopies in an outpatient setting without decreasing recurrence-free survival or increasing risk of progression.

  • 1 views
  • 24 Jan, 2021
  • 3 locations
Durvalumab and Vicinium in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

Background Non-muscle-invasive bladder cancer is in the early stages. But it usually comes back after treatment. The drugs Vicinium and Durvalumab may help the immune system find and destroy cancer cells. Objective To test if the drugs Durvalumab and Vicinium together are safe and effective to treat people with bladder …

intravesical bcg
invasive bladder cancer
bcg vaccine
durvalumab
carcinoma
  • 255 views
  • 16 May, 2021
  • 1 location
Predicting BCG Response

To date, there are no diagnostics capable of predicting treatment response to intravesical BCG. Because of this severe limitation, nearly 50% of patients treated with BCG fail therapy and will a

intravesical bcg
carcinoma in situ
bladder tumor
carcinoma
antineoplastic
  • 0 views
  • 01 May, 2021
  • 1 location